|
|
|
Volumn 1, Issue 1, 2001, Pages 3-
|
|
Berlex Laboratories to market new treatment for B-CLL.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALEMTUZUMAB;
ANTINEOPLASTIC AGENT;
CANCER ANTIBODY;
MONOCLONAL ANTIBODY;
ADULT;
ARTICLE;
B CELL LEUKEMIA;
DRUG APPROVAL;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
UNITED STATES;
ADULT;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, NEOPLASM;
ANTINEOPLASTIC AGENTS;
DRUG APPROVAL;
HUMANS;
LEUKEMIA, B-CELL, CHRONIC;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 0035372509
PISSN: 14737140
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (1)
|
|
References (0)
|